Edwards Lifesciences (NYSE:EW) Given New $105.00 Price Target at Mizuho

Edwards Lifesciences (NYSE:EW) had its price objective boosted by research analysts at Mizuho from $100.00 to $105.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the medical research company’s stock. Mizuho’s price objective suggests a potential upside of 19.34% from the stock’s previous close.

A number of other research analysts have also recently commented on the stock. BTIG Research raised their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Royal Bank Of Canada raised their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research note on Monday. Truist Financial set a $90.00 price target on Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Barclays reiterated an “overweight” rating and issued a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $98.73.

Edwards Lifesciences Stock Down 2.3%

EW stock traded down $2.11 during mid-day trading on Wednesday, hitting $87.98. The stock had a trading volume of 3,778,044 shares, compared to its average volume of 4,833,209. The stock has a market capitalization of $50.66 billion, a price-to-earnings ratio of 46.84, a PEG ratio of 2.30 and a beta of 0.86. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 1-year low of $72.30 and a 1-year high of $96.29. The company has a fifty day moving average of $87.04 and a 200 day moving average of $83.92.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.60 billion. During the same quarter in the previous year, the business earned $0.64 EPS. Edwards Lifesciences’s quarterly revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, equities analysts expect that Edwards Lifesciences will post 3 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 619 shares of the company’s stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $91.70, for a total transaction of $56,762.30. Following the completion of the sale, the vice president owned 40,034 shares of the company’s stock, valued at approximately $3,671,117.80. This represents a 1.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the sale, the senior vice president owned 15,334 shares in the company, valued at $1,319,950.72. This represents a 3.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 45,577 shares of company stock worth $3,855,527 over the last ninety days. Corporate insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Investors Research Corp raised its position in shares of Edwards Lifesciences by 855.3% during the second quarter. Investors Research Corp now owns 898 shares of the medical research company’s stock worth $81,000 after acquiring an additional 804 shares during the last quarter. Handelsbanken Fonder AB boosted its position in shares of Edwards Lifesciences by 22.0% during the 2nd quarter. Handelsbanken Fonder AB now owns 1,541,212 shares of the medical research company’s stock valued at $139,418,000 after purchasing an additional 278,208 shares in the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors boosted its position in shares of Edwards Lifesciences by 37.1% during the 2nd quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 7,208 shares of the medical research company’s stock valued at $652,000 after purchasing an additional 1,950 shares in the last quarter. Revolve Wealth Partners LLC acquired a new stake in Edwards Lifesciences during the second quarter worth approximately $206,000. Finally, Everpar Advisors LLC acquired a new stake in Edwards Lifesciences during the second quarter worth approximately $267,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.